Presentations—Checkpoint Inhibitors in Adv/Met Lung Cancer
prIME Downloadable Slides
prIME Downloadable Slides

Presentations—Checkpoint Inhibitors in Adv/Met Lung Cancer

Evaluating Current and Emerging Strategies in the Fight Against Advanced/Metastatic Lung Cancer

Not a member of My prIME? Join now for instant access.

Explore the latest updates on using checkpoint inhibitors in lung cancer with these downloadable slides presented at our symposium held at the European Society for Medical Oncology on September 9, 2017, in Madrid, Spain.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Sep 11, 2017

Expiration Date

Sep 11, 2018

Featured Expert

  • Enriqueta Felip, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Current uses of checkpoint inhibitor therapy in the treatment of non-small cell lung cancer (NSCLC)

Featured Expert

  • Marina Garassino, MD, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

Featured Topic

Biomarkers in clinical practice: Benefits and limitations

Featured Expert

  • Jürgen R. Fischer, MD, Klinik Löwenstein gGmbH, Löwenstein, Germany

Featured Topic

Early identification and optimal management of immune-related adverse events (irAEs)

Featured Expert

  • Naiyer Rizvi, MD, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York, United States

Featured Topic

Safety and efficacy of emerging checkpoint inhibitors in NSCLC

Featured Expert

  • David Planchard, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

prIME Points™

This educational activity is specifically designed to meet the needs of medical oncologists, pulmonologists, and other multidisciplinary specialists involved in the treatment of patients with NSCLC.

After successful completion of this educational activity, participants should be able to:

  • Assess recent data on the efficacy/safety of checkpoint inhibitor therapy for the treatment of NSCLC
  • Implement appropriate treatments for NSCLC that incorporate the use of checkpoint inhibitors
  • Describe the benefits and limitations of using PD-L1 as a biomarker to guide treatment selection when managing NSCLC
  • Develop management strategies to address irAEs related to the use of checkpoint inhibitors
  • Analyze recent efficacy and safety data on emerging checkpoint inhibitors, alone and in combination with other agents, in the treatment of NSCLC

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Felip has disclosed that she received consulting fees from Boehringer Ingelheim, Eli Lilly, MSD, Pfizer, and Roche. She also received lecture fees for participating in speaker bureaus from AstraZeneca, Bristol-Myers Squibb, and Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fischer has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Celgene, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Garassino has disclosed receipt of consulting fees, research support or performance of contracted research, and fees for non-CME services for her role on advisory boards from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Inivata Limited, MSD, MSD International GmbH, Novartis, Novartis Farma, Otsuka Pharma, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Planchard has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer, MSD, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rizvi has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, and Roche. He also has ownership interest in ARMO Biosciences and Gritstone Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.